Latest papers

Pharmacological MRI in animal models: a useful tool for 5-HT research?

Drug addiction and brain targets: from preclinical research to pharmacotherapy.

The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.

Differential neuropsychopharmacological influences of naturally occurring tropane alkaloids anisodamine versus scopolamine.

Drugs used to treat Parkinson's disease, present status and future directions.

Methodological optimization of applying neuroactive agents for the study of locomotor-like activity in the mudpuppies (Necturus maculatus).

Profile: Jacqueline French: pioneering trial protocols for epilepsy.

Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK.

Abstracts of the 21st European College of Neuropsychopharmacology Congress, 30 August-3 September 2008, Barcelona, Spain.

Considerations in the choice of an antiepileptic drug in the treatment of epilepsy.

Abstracts from the XXVI CINP (Collegium Internationale Neuro-psychopharmacologium) Congress, 13-17 July 2008, Munich, Germany.

A review of the neuropharmacological properties of khat.

Advances in neurobiology, assessment and treatment of female-specific mood disorders: papers from a symposium presented at the joint congress of the Collegium Internationale Neuro-Psychopharmacologicum and the Canadian College of Neuropsychopharmacology, Chicago, July 11, 2006.

Canadian College of Neuropsychopharmacology: 2008 award winners.

The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs.

An optimized recording method to characterize biophysical and pharmacological properties of acid-sensing ion channel.

Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology content over the Internet.

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.

Systematic review of therapeutic interventions in human prion disease.

Strategy for utilization of new antiepileptic drugs.